瑞丰银行(601528) 报告日期：2025 年 08 月 27 日 息差企稳，不良波动 ——瑞丰银行 25H1 业绩点评 投资要点 ❑ 25H1 瑞丰银行营收、归母净利润同比增速有所放缓，息差韧性较强。 ❑ 业绩概览 25H1 营收、归母净利润同比+3.9%、+5.6%，增速环比 25Q1 放缓 1.2pc、1.1pc； 25Q2 末不良率环比+1bp 至 0.98%，25Q2 末拨备覆盖率环比提升 14pc 至 340%。 ❑ 盈利增速放缓 25H1 瑞丰银行营收、归母净利润同比分别+3.9%、+5.6%，增速环比 25Q1 放缓 1.2pc、1.1pc。驱动因素来看，规模增长放缓、非息增速放缓拖累盈利表现。 ❑ 息差环比企稳 瑞丰银行 25H1 息差环比 25Q1 持平于 1.46%，息差韧性较强，主要得益于存款成 本改善，有效对冲资产端收益率下行影响。 （1）资产端。测算 25Q2 资产端收益率环比下降 9bp 至 3.19%，主要源于贷款利 率行业性下行。25H1瑞丰银行贷款收益率较24H2下降29bp，其中对公贷款（不 含票据贴现）、零售贷款分别下降 32bp、35bp。 （2）负债端。测算 25 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation of stock price appreciation exceeding 15% over the next six months [5]. Core Insights - The company's operating profit continues to grow, with a reported revenue of 1.666 billion yuan for the first half of 2025, representing a year-on-year increase of 16.13%. However, the net profit attributable to shareholders decreased by 6.01% to 146 million yuan [1][2]. - The decline in net profit is primarily attributed to foreign exchange losses this year compared to gains in the same period last year. The significant drop in non-recurring net profit is due to changes in the structure of financial products [2]. - The company announced a cash dividend of 0.1 yuan per share, totaling 19 million yuan, which exceeds the total dividend for the entire year of 2024, with a payout ratio of 13.3% [1]. Financial Performance Summary - For Q2 2025, the company achieved a revenue of 873 million yuan, up 8.98% year-on-year, while the net profit attributable to shareholders was 74 million yuan, down 11.28% [1]. - The company reported a historical high in single-quarter revenue, driven by strong growth in decorative building materials and overseas markets, with non-US market revenue increasing by 31.15% year-on-year [3]. - The Vietnam subsidiary, which primarily exports to the US, generated 210 million yuan in revenue for H1 2025, marking a 49% increase year-on-year [3]. Future Outlook - The report highlights the company's advantages in the recycling-granulation-product chain and the potential for growth through new products and overseas capacity expansion. The company aims for a compound annual growth rate of 15% in revenue or net profit over the next five years [4]. - Forecasted net profits for 2025-2027 are 330 million, 374 million, and 448 million yuan, respectively, with corresponding price-to-earnings ratios of 16.98, 15.00, and 12.52 [4].

Investment Rating - The report maintains a "Buy" rating for the company, expecting significant price appreciation over the next six months [12][4]. Core Insights - The company achieved a revenue of 1.247 billion yuan in H1 2025, a year-on-year decrease of 3.64%, while the net profit attributable to shareholders increased by 10.01% to 445 million yuan [1][2]. - The gross margin improved to 51.26%, up 3.78 percentage points year-on-year, and the net profit margin reached 35.97%, an increase of 4.32 percentage points, driven by a higher proportion of high-margin products in life sciences, metal resources, and ultra-pure water [2][3]. - The operating cash flow for the period was 288 million yuan, reflecting a 36.50% year-on-year increase, with a low debt ratio of 36.30% [2][3]. Revenue Breakdown - The basic warehouse business showed steady growth, with life sciences, metal resources, and water treatment maintaining a high growth trajectory. Excluding the impact of unrecognized revenue from the large lithium extraction project, revenue grew by 4.26% year-on-year [3]. - The metal resources segment generated 149 million yuan in revenue, a year-on-year increase of 22.84%, with ongoing projects in lithium extraction and other industrialization efforts [3]. - The life sciences segment reported revenue of 320 million yuan, up 12.43% year-on-year, supported by the growth of peptide synthesis projects [3]. - The water treatment and ultra-purification segment achieved revenue of 359 million yuan, an increase of 11.25% year-on-year, with significant contracts established with leading clients [3]. Financial Forecast - The company is projected to achieve net profits of 1.054 billion yuan, 1.341 billion yuan, and 1.608 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 25.14X, 19.76X, and 16.48X [4][5].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6] Core Views - The company has shown steady growth in revenue and performance, with a focus on expanding its presence in the central and western regions of China, benefiting from the improving infrastructure landscape [1][2] - For the first half of 2025, the company achieved a revenue of 924 million, a year-on-year increase of 2.64%, and a net profit attributable to the parent company of 133 million, up 5.29% year-on-year [1] - The company is expected to enhance its profitability further as its fundraising projects are implemented, leveraging its leading position to increase market share [1] Financial Performance Summary - In the first half of 2025, the company reported revenues from various segments: surveying and design (460 million, -2.07% YoY), engineering supervision (150 million, -1.21% YoY), technical services (114 million, +9.97% YoY), and other businesses (132 million, +52.74% YoY) [2] - The overall gross margin for the first half of 2025 was 42.5%, an increase of 2.39 percentage points year-on-year, with the second quarter gross margin rising to 42.92% [2] - The company maintained good expense control, with a total expense ratio of 16.26%, down 1.63 percentage points year-on-year, and a net profit margin of 14.42%, up 0.34 percentage points year-on-year [3] Future Earnings Forecast - The forecast for net profit attributable to the parent company for 2025-2027 is 247 million, 266 million, and 289 million respectively, with corresponding P/E ratios of 18, 17, and 15.6 [1]

Investment Rating - The report maintains a "Buy" rating for the company, with expected EPS for 2025-2027 at 1.86, 2.12, and 2.43 RMB respectively, corresponding to PE ratios of 13, 12, and 10 times [6]. Core Viewpoints - The company has shown steady revenue growth in H1 2025, with a revenue increase of 7.10% year-on-year, and a net profit increase of 11.42% [2]. - The recovery of downstream demand is expected to support stable revenue growth, particularly in eco-friendly packaging, which is anticipated to continue expanding [3]. - The company has implemented a new equity incentive plan, reflecting confidence in long-term development and a clear path for valuation uplift [5]. Performance Summary - In H1 2025, the company reported revenues of 7.876 billion RMB and a net profit of 554 million RMB, with a proposed cash dividend of 0.43 RMB per share, resulting in a payout ratio of 70.18% [2]. - The revenue from paper-based premium packaging, packaging supporting products, and eco-friendly paper-plastic products was 5.461 billion RMB, 1.297 billion RMB, and 584 million RMB respectively, with year-on-year growth rates of 5.39%, -6.70%, and 6.77% [3]. - The gross margin for H1 2025 was 22.77%, with a net margin of 6.80%, showing slight declines compared to the previous year [4]. Financial Projections - The company is projected to achieve revenues of 19.002 billion RMB in 2025, with a growth rate of 10.75% [11]. - The diluted EPS is expected to grow from 1.864 RMB in 2025 to 2.425 RMB in 2027, indicating a positive growth trajectory [11]. - The company’s return on equity (ROE) is projected to be 14.10% in 2025, with a P/E ratio of 13.24 [11].

Investment Rating - The report assigns an "Accumulate" rating to the company [1] Core Views - The company has made significant investments in high-performance GPU technology through its 37.88% stake in Shanghai Lishuan, which is focused on developing scalable graphics rendering GPU chips [5] - The company's revenue for the first half of 2025 reached 343 million yuan, representing a year-on-year increase of 28.81%, with the second quarter showing a revenue of 201 million yuan, up 25.43% year-on-year and 41.11% quarter-on-quarter [4][6] - The semiconductor market is gradually recovering, driven by demand recovery in industrial markets and AI applications, leading to improved sales prices and profitability for the company's main products [6] Company Overview - The latest closing price of the company's stock is 100.02 yuan, with a total market capitalization of 44.2 billion yuan [3] - The company has a debt-to-asset ratio of 4.6% and a current P/E ratio of -263.21 [3] Financial Projections - Revenue projections for 2025-2027 are estimated at 858 million yuan, 1.121 billion yuan, and 1.406 billion yuan respectively, with a gradual recovery in profits expected [9] - The company is expected to achieve a net profit of 86 million yuan by 2027, indicating a significant turnaround from previous losses [9] Product Development - The company has successfully launched its first self-developed GPU chip "7G100" and is currently in the process of customer sampling and mass production [5] - Continuous updates and iterations in storage technology are being pursued, including the mass production of 1xnm flash memory products and ongoing development of SLC NAND Flash and NOR Flash products [7][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company's net profit attributable to shareholders increased by 25% year-on-year in the first half of 2025, aligning with market expectations [2] - The company aims to achieve a revenue target of 60 billion yuan by 2030, with international revenue accounting for over 60% [4] Financial Performance Summary - In H1 2025, total revenue reached 18.18 billion yuan, a year-on-year increase of 13.2%, while net profit attributable to shareholders was 1.23 billion yuan, up 25% [2] - For Q2 2025, total revenue was 9.03 billion yuan, a year-on-year increase of 11.2%, and net profit was 570 million yuan, up 17.9% [2] - Domestic revenue for H1 2025 was 9.66 billion yuan, up 15.7%, while overseas revenue was 8.52 billion yuan, up 10.5% [2] - The sales gross margin for H1 2025 was 22.3%, a year-on-year increase of 0.2 percentage points [3] - The company plans to invest 500 million yuan in building a manufacturing plant in Indonesia to enhance local manufacturing capabilities [4] Earnings Forecast and Valuation - The revised net profit forecasts for 2025-2027 are 1.85 billion yuan, 2.76 billion yuan, and 3.55 billion yuan, respectively [5] - The current market capitalization corresponds to P/E ratios of 12, 8, and 6 times for 2025, 2026, and 2027, respectively [5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [3]. Core Insights - The company reported a revenue of 266 million yuan for the first half of 2025, reflecting a year-on-year growth of 20.5%. The net profit attributable to shareholders was 74 million yuan, with a growth of 5.5% [3]. - The medical endoscope segment generated 207 million yuan in revenue, up 17.7% year-on-year, while the optical segment saw a revenue increase of 34.6% to 57 million yuan [3]. - The gross margin improved to 65.8% in the first half of 2025, slightly up from 64.5% in 2024, attributed to a higher proportion of high-margin products and effective cost management [3]. - The company has initiated the production of endoscopes in its Thailand facility, which is expected to mitigate tariff impacts and enhance long-term growth prospects [3]. Financial Data and Profit Forecast - Projected total revenue for 2025 is estimated at 671 million yuan, with a year-on-year growth rate of 27.5% [2]. - The forecasted net profit for 2025 is 172 million yuan, representing a growth of 27.4% compared to the previous year [2]. - Earnings per share (EPS) is expected to reach 1.44 yuan in 2025, with a consistent growth trajectory anticipated through 2027 [2]. - The company's return on equity (ROE) is projected to improve to 12.3% in 2025, indicating enhanced profitability [2].

Investment Rating - The report maintains a "Buy" rating for the company [1][7][8] Core Views - The company has released performance pressure in Q2 2025, with its core product series showing resilience in the Anhui market [3][7] - Despite a decline in revenue and net profit, the company is focusing on its core products and optimizing its organizational structure [5][7] Financial Performance Summary - For H1 2025, the company reported total revenue of 3.16 billion yuan, a year-on-year decrease of 16.51%, and a net profit of 1.13 billion yuan, down 18.02% [2][5] - In Q2 2025, total revenue was 1.11 billion yuan, a decline of 23.81%, with net profit at 302 million yuan, down 35.22% [2][5] - The company’s sales gross margin decreased by 2.82 percentage points to 68.33% in Q2 2025, attributed to weak demand affecting product structure [5][7] Market and Product Insights - In Q2 2025, the mid-to-high-end and regular product segments generated revenues of 817 million yuan and 210 million yuan, respectively, with year-on-year declines of 23.60% and 32.90% [5] - The company’s revenue from the Anhui market in Q2 2025 was 730 million yuan, down 20.29%, while revenue from outside Anhui was 296 million yuan, down 36.38% [5] - The company is focusing on the洞藏 series core products and has implemented strict price management [5][7] Future Earnings Forecast - The company’s projected revenues for 2025, 2026, and 2027 are 6.154 billion yuan, 6.468 billion yuan, and 7.069 billion yuan, respectively, with corresponding net profits of 2.128 billion yuan, 2.294 billion yuan, and 2.561 billion yuan [6][7] - The expected EPS for 2025, 2026, and 2027 are 2.66 yuan, 2.87 yuan, and 3.20 yuan, respectively [6][7]

Investment Rating - The report maintains an "Accumulate" investment rating for the company [3][7]. Core Views - The company achieved a total revenue of 567 million yuan in the first half of 2025, representing a year-on-year increase of 20.40%. However, the net profit attributable to shareholders decreased by 64.57% year-on-year to 8.14 million yuan due to market conditions and increased competition [1][7]. - The electronic wet chemical segment generated revenue of 434.15 million yuan, up 25.57% year-on-year, while the electronic specialty gases and precursors segment saw revenue of 120.42 million yuan, a 10.49% increase year-on-year [7]. - The company is focusing on R&D, with R&D expenses amounting to 40.60 million yuan, which is 7.17% of total revenue, reflecting a 38.70% increase year-on-year [7]. - The company is expected to achieve revenues of 1.29 billion yuan, 1.62 billion yuan, and 1.95 billion yuan in 2025, 2026, and 2027 respectively, with year-on-year growth rates of 26%, 25%, and 20% [7][8]. Financial Data and Valuation - The company’s total revenue is projected to grow from 894 million yuan in 2023 to 1.95 billion yuan in 2027, with corresponding year-on-year growth rates of 12%, 15%, 26%, 25%, and 20% [2][10]. - The net profit attributable to shareholders is expected to increase from 14 million yuan in 2023 to 24 million yuan in 2027, with growth rates of 30%, -27%, 21%, 53%, and 31% respectively [8][11]. - The company’s PE ratios for 2025, 2026, and 2027 are projected to be 1100.2, 718.1, and 548.1 respectively, indicating a valuation above the industry average [7][11]. Stock Performance - The company's stock has shown a 14% absolute performance over the past month, a -1% performance over six months, and a 58% performance over the past year [5].